(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
The most effective method to Pick the Right Old Consideration Administration: Key Contemplations- The most effective method to Recognize a Great Lab Jewel
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- 4 Energy-Proficient Clothes washers to Consider in 2024
- 5 Arising Vocations in Sustainable power
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Monetary Strength: Get ready for Life's Unforeseen Difficulties
- Turning into a Sharp Financial backer: Individual budget Wins
